Share

November 2020; 7 (6) ArticleOpen Access

Bickerstaff brainstem encephalitis with or without anti-GQ1b antibody

Keisuke Yoshikawa, Motoi Kuwahara, Miyuki Morikawa, Susumu Kusunoki
First published September 15, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000889
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2239

Share

Article Information

vol. 7 no. 6 e889
DOI: 
https://doi.org/10.1212/NXI.0000000000000889
PubMed: 
32934014
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received June 16, 2020
  • Accepted in final form August 18, 2020
  • First Published September 15, 2020.
Copyright & Usage: 
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Keisuke Yoshikawa, MD, PhD,
    2. Motoi Kuwahara, MD, PhD,
    3. Miyuki Morikawa, MD, PhD and
    4. Susumu Kusunoki, MD, PhD
  1. Keisuke Yoshikawa, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Motoi Kuwahara, MD, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)Teijin, speaker honoraria (2)Nihon Pharmaceutical, speaker honoraria (3)Japan Blood Products Organization, speaker honoraria (4)CSL Behring, speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Miyuki Morikawa, MD, PhD and
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Susumu Kusunoki, MD, PhD
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)Teijin Pharma, speaker honoraria, (2) Nihon Pharmaceuticals, speaker honoraria, (3) Japan Blood Products Organization, speaker honoraria, (4) Biogen, speaker honoraria, (5) Novartis, speaker honoraria, (6) Dainippon Sumitomo, speaker honoraria, (7) Kyowa Kirin, speaker honoraria, (8) CSL Behring, speaker honoraria, (9) Pfizer, speaker honoraria, (10) Alexion, speaker honoraria, and (11) Chugai, speaker honoraria

    Editorial Boards:

    1. (1) Journal of Neuroimmunology, editorial board member, 11 years, (2) Neurology and Clinical Neuroscience, editor-in-chief, 2 years, (3) JMA Journal, 2 years

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis, (2) Dainippon Sumitomo Pharma, (3)Sanofi, (4) Japan Blood Products Organization, (5) Ohtsuka, (6) Kyowa Kirin, (7) Daiichi Sankyo, (8) Eisai, (9) Takeda, and (10) Nihon Pharmaceuticals

    Research Support, Government Entities:

    1. (1)Ministry of Education, Culture, Sports, Science and Technology of Japan, 18H02745, principal investigator, 2018-2020

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology, Kindai University Faculty of Medicine, Osaka, Japan.
  1. Correspondence
    Dr. Kusunoki kusunoki-tky{at}umin.ac.jp
View Full Text

Article usage

Article usage: September 2020 to August 2023

AbstractFullPdfSource
Sep 20202731478Highwire
Oct 20201157189Highwire
Nov 2020529681Highwire
Dec 20201316138Highwire
Jan 20211624751Highwire
Feb 2021417744Highwire
Mar 2021215635Highwire
Apr 2021813850Highwire
May 20211818437Highwire
Jun 2021824753Highwire
Jul 2021626045Highwire
Aug 20211230961Highwire
Sep 20211027051Highwire
Oct 2021527379Highwire
Nov 2021518747Highwire
Dec 20211026260Highwire
Jan 20221037478Highwire
Feb 2022826665Highwire
Mar 2022534053Highwire
Apr 2022624634Highwire
May 2022049369Highwire
Jun 2022642064Highwire
Jul 20221043745Highwire
Aug 2022473964Highwire
Sep 2022746568Highwire
Oct 2022746963Highwire
Nov 20221353479Highwire
Dec 2022842463Highwire
Jan 20231257572Highwire
Feb 20231053654Highwire
Mar 2023463464Highwire
Apr 2023453178Highwire
May 2023557082Highwire
Jun 20231559280Highwire
Jul 20231751577Highwire
Aug 2023758488Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles